229 related articles for article (PubMed ID: 21770080)
1. What drug labels don't tell you.
Consum Rep; 2011 Aug; 76(8):10. PubMed ID: 21770080
[No Abstract] [Full Text] [Related]
2. MedGuide: at last a long-sought opportunity for patient education about prescription drugs.
Marwick C
JAMA; 1997 Mar; 277(12):949-50. PubMed ID: 9091654
[No Abstract] [Full Text] [Related]
3. Stoning a dead bird: advertising limits on approved new drugs.
Strobos J
Food Drug Law J; 1995; 50(4):533-51. PubMed ID: 10343018
[No Abstract] [Full Text] [Related]
4. Rules set for dissemination of off-label-use information.
Miller JL
Am J Health Syst Pharm; 1999 Feb; 56(3):204. PubMed ID: 10030500
[No Abstract] [Full Text] [Related]
5. Patient package inserts: the proper prescription?
Rowe HM
Food Drug Law J; 1995; 50(1):95-124. PubMed ID: 10342988
[No Abstract] [Full Text] [Related]
6. Regulation of pharmacoeconomics and outcomes research.
Radensky P
Value Health; 2001; 4(1):12-5. PubMed ID: 11704968
[No Abstract] [Full Text] [Related]
7. Should expiration dates be required on patients' prescription labels?
Hadeler F
Am Pharm; 1986 Aug; NS26(8):30-5. PubMed ID: 3776829
[No Abstract] [Full Text] [Related]
8. FDA off-track on off-label drug promotion.
Lancet; 2007 Dec; 370(9604):1976. PubMed ID: 18083382
[No Abstract] [Full Text] [Related]
9. FDA's Rx for better medication information.
Farley D
FDA Consum; 1995 Nov; 29(9):5-10. PubMed ID: 10152787
[TBL] [Abstract][Full Text] [Related]
10. Off-label or off-limits?
Ratner M; Gura T
Nat Biotechnol; 2008 Aug; 26(8):867-75. PubMed ID: 18688236
[No Abstract] [Full Text] [Related]
11. Direct-to-consumer prescription drug advertising.
Terzian TV
Am J Law Med; 1999; 25(1):149-67. PubMed ID: 10207573
[No Abstract] [Full Text] [Related]
12. Lessons from cisapride.
CMAJ; 2001 May; 164(9):1269, 1271. PubMed ID: 11341130
[No Abstract] [Full Text] [Related]
13. Prescription drug products; patient labeling requirements: proposed rule.
Fed Regist; 1979 Jul; 44(131 Pt 2):40015-41. PubMed ID: 10242793
[No Abstract] [Full Text] [Related]
14. Use of drugs for unlabeled indications.
Nightingale SL
Am Fam Physician; 1986 Sep; 34(3):269. PubMed ID: 3751849
[No Abstract] [Full Text] [Related]
15. FDA proposes more stringent pediatric-use labeling of prescription drug products.
Clin Pharm; 1993 Jan; 12(1):6. PubMed ID: 8428434
[No Abstract] [Full Text] [Related]
16. Black box warnings in prescription drug labeling: results of a survey of 206 drugs.
Beach JE; Faich GA; Bormel FG; Sasinowski FJ
Food Drug Law J; 1998; 53(3):403-11. PubMed ID: 10346718
[No Abstract] [Full Text] [Related]
17. FDA requires boxed warning for all immediate-release opioid products.
Thompson CA
Am J Health Syst Pharm; 2016 May; 73(9):e114-5. PubMed ID: 27099322
[No Abstract] [Full Text] [Related]
18. A defense of the learned intermediary doctrine.
Goetz RB; Growdon KR
Food Drug Law J; 2008; 63(2):421-38. PubMed ID: 18561470
[No Abstract] [Full Text] [Related]
19. FDA proposes more stringent pediatric-use labeling of prescription drug products.
Am J Hosp Pharm; 1993 Jan; 50(1):13, 16. PubMed ID: 8427271
[No Abstract] [Full Text] [Related]
20. The patient package insert--health care provider's friend or foe?
Hirsh HL
Nurs Homes; 1979; 28(4):24-5. PubMed ID: 10283734
[No Abstract] [Full Text] [Related]
[Next] [New Search]
